Recombinant proteins manufacturing FAQs

Purification is typically designed backwards from the required product quality, as higher quality demands typically require more purification steps. The process combines operations that recover the product while clearing host-cell proteins, DNA, aggregates, endotoxin where relevant, and other process-related impurities.

An affinity capture step can be efficient when a suitable ligand or tag is available, but commercial products may require a tag-free or platform-specific strategy. Ion exchange, hydrophobic interaction, multimodal, and size-based separations are selected according to the molecule’s charge, size, stability, and impurity profile. Ultrafiltration and diafiltration concentrate the product and exchange it into the required buffer. Each additional unit operation may improve clearance but can reduce yield, lengthen processing, and increase cost. The aim is therefore the minimum robust sequence that meets quality requirements at scale, not the largest possible number of purification steps.

The best expression system is selected by matching the protein’s structural and functional requirements with host capability, scalable recovery and long-term cost. Glycosylation, folding, disulphide bonds, toxicity, secretion and target dose usually drive the decision. Ultimately a range of different host and systems might need to be tested.

E. coli can offer rapid, cost-efficient production when complex mammalian processing is not required. CHO is often chosen for antibodies and glycoproteins that need mammalian folding and glycosylation, while HEK293 may suit selected complex proteins or viral applications. A system with the highest expression signal may still lose on usable yield if purification, refolding or product heterogeneity is difficult. Regulatory history, platform licences, cell-bank strategy and facility fit also affect the choice. Feasibility data should compare active purified product and relevant quality attributes rather than total expression alone.

A new programme can range from several months for a tractable microbial product with a mature analytical strategy to a year for a new stable mammalian cell line and full GMP package. The critical path is set by expression-system readiness, cell banking, process complexity, assay development, raw materials and manufacturing access.

Early non-GMP material may be available in weeks or a few months, but it is not the same milestone as a released clinical batch. Stable CHO clone selection alone often takes about four to six months before banking and full characterisation are complete. A microbial route can be shorter, and NorthX states that its integrated enGenes pathway can avoid three to six months of handover time compared with fragmented delivery. Potency assays, viral-safety work, stability data or hard-to-source materials can become longer lead-time items than the production run itself. A realistic schedule should show decision points, parallel workstreams and release activities separately.

Titre is the amount of product present in the culture or fermentation harvest, purity is the proportion of the target protein in the tested sample, and overall yield is the amount of acceptable product recovered after the full process. A high titre does not guarantee a high final yield or a suitable product.

Titre is useful for upstream comparison but does not account for insoluble, inactive or difficult-to-purify material. Step yield shows recovery across one unit operation, while overall process yield multiplies losses across harvest, purification and formulation. Purity must be interpreted together with potency, aggregates, variants and residual impurities. An apparent upstream improvement can increase downstream loss if it also increases aggregation or contaminant burden. Process decisions should therefore use grams of released-quality product per batch or per unit cost where possible, not titre alone.

Recombinant protein manufacturing uses an engineered host cell to produce a defined protein from an introduced genetic sequence. The process includes expression-system development, cell culture or fermentation, harvest, purification, formulation, testing and, when required, GMP manufacture.

Common hosts include E. coli for many non-glycosylated proteins and CHO or HEK293 cells for more complex mammalian proteins. The manufacturing process must consistently deliver the intended product with the correct structure, activity and impurity profile, not simply a high amount of protein. Upstream and downstream steps are therefore developed as one connected process. Analytical methods track identity, purity, potency, content, product variants and process-related impurities. For clinical use, cell-bank control, raw-material traceability, batch records, release testing and stability data become part of the CMC package.

Non-GMP material may be suitable for research, assay development or selected non-clinical work, while GMP material is manufactured and controlled under an approved pharmaceutical quality system for its intended clinical or commercial use. The difference is the controlled system and documented evidence, not simply a final purity result.

GMP manufacture requires approved instructions, qualified facilities and equipment, trained personnel, controlled materials, deviation handling, data integrity and quality-unit oversight. The batch is tested against approved specifications and released through a defined quality process. Phase-appropriate GMP allows the depth of control and validation to grow with product knowledge and patient exposure, but it does not mean that core requirements can be ignored. Using research-grade starting materials or methods too late can force bridging, replacement or repeated studies. The material grade should therefore be matched to the exact study, jurisdiction and development stage before production begins.

Upstream processing creates the protein through cell growth and expression, while downstream processing recovers, purifies, and formulates it. The two must be developed together because upstream conditions determine the product and impurity load entering purification. As such, part of DSP might be in a fermentation facility, depending on what is best for the product.

Upstream work covers the production host, media, feeding, culture mode, process parameters, and harvest timing. Downstream work covers clarification, capture, intermediate purification, polishing, concentration and buffer exchange. A small upstream change can alter aggregates, charge variants, glycosylation, host-cell proteins, or DNA and therefore change downstream performance. Conversely, a purification bottleneck may justify changing the expression location, harvest point or culture conditions. An integrated process uses shared material plans and critical quality attributes to keep both workstreams aligned.

A useful technology-transfer package contains the process, methods, materials, equipment assumptions, cell-bank or strain history, product knowledge, prior deviations and acceptance criteria needed to reproduce the product. It should explain why the process works, not only list operating instructions.

Core documents normally include process descriptions, batch records, analytical methods, specifications, development reports and raw-material information. Scale history, critical parameters, hold times, sampling plans, cleaning needs and known failure modes are equally important. The receiving site performs a gap and risk assessment against its equipment, utilities, quality system and biosafety controls. Missing tacit knowledge is often recovered through scientist-to-scientist sessions and observation of the process. Transfer is complete only when the receiving team can execute the process reproducibly and the agreed acceptance criteria are met.

Formulation and stability work should begin early enough to support material storage, non-clinical studies and the first GMP campaign, not after purification is already fixed. Early screens can identify pH, buffer, concentration and handling conditions that prevent avoidable degradation.

Proteins may aggregate, oxidise, deamidate, adsorb to surfaces or lose activity during freezing, thawing and transport. A formulation screen compares buffers, excipients, concentration and stress conditions using stability-indicating methods. The selected formulation must also fit the downstream process, container-closure system and intended route of administration. Formal real-time and accelerated stability studies then support retest periods or shelf life as development progresses. Starting late can delay clinical supply because a released batch still needs justified storage and shipping conditions.

Recombinant protein testing normally covers identity, quantity, purity, potency, structural integrity, product variants, process-related impurities and microbiological safety. The exact panel is product-specific and becomes more complete as the programme advances.

Identity may be confirmed using a one or several methods, including mass-based methods, sequencing or orthogonal immunochemical techniques, HPLC methods or other. Purity and heterogeneity can require size-exclusion chromatography, electrophoresis, capillary methods, charge analysis and aggregate testing. Potency should measure a function linked as closely as possible to the intended mechanism of action. Host-cell protein, residual DNA, endotoxin, bioburden and other process-specific impurities are assessed according to the host and process. Specifications select a justified subset of these attributes for release, while wider characterisation builds understanding and supports comparability.

Glycosylation, charge variants, oxidation, deamidation, clipping and aggregation can change a protein’s activity, stability, pharmacokinetics or immunogenicity. These variants must be understood and controlled when they affect product performance or patient risk.

Mammalian host, clone, media and culture conditions can all change the glycan profile of a protein. Processing time, temperature, pH, light and shear can create additional chemical or physical variants during purification and storage. Not every detected variant is clinically meaningful, so development links analytical results to biological function and prior knowledge. Critical variants are monitored through process controls and, where appropriate, release specifications. Manufacturing changes may require a comparability exercise to show that product quality remains sufficiently similar.

Analytical methods should start early because process development cannot optimise what it cannot measure. Fit-for-purpose methods allow teams to compare candidates, track impurities and make evidence-based decisions before GMP manufacture.

Early methods may be qualified only for the decision they support, while later release methods require more formal validation. A potency assay is often schedule-critical because biological variability and reference-standard strategy take time to resolve. Stability-indicating methods are needed before formulation and formal stability studies can generate useful data. Close coordination between analytical development and quality control reduces friction when methods transfer into the GMP release laboratory. NorthX states that its analytical development and QC teams work together in alignment with ICH Q14 and ICH Q2(R2).